Project Grant R01DK124427
- This Project Grant award, valued at $275,275 and provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of a miniaturized and flexible continuous glucose monitoring (CGM) platform called "GlucoSoft" by Integrated Medical Sensors Inc., a minority-owned small disadvantaged business. The goal is to create a scalable, user-friendly, and...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $165,541 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Scripps Health, a nonprofit health system based in San Diego, California. The grant funding will be used to integrate continuous glucose monitoring (CGM) education into the Project DULCE diabetes self-management program to improve glycemic control in Latino adults with type 2 diabetes. Key...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $284,999 to Integrated Medical Sensors Inc. to develop and validate efficient algorithms for real-time glucose monitoring on a multi-sensor integrated platform. The goal is to create a scalable, user-friendly, and affordable continuous glucose monitoring (CGM) system to improve...
- This National Science Foundation (NSF) Division of Social and Economic Science Project Grant awarded to Emory University for $231,685 examines how different organizations, such as medical clinics, technology companies, and schools, influence access to and use of medical devices for youth with diabetes. The two-phased project focuses on continuous glucose monitoring (CGM) devices and insulin pumps, investigating how these organizations and their interactions shape health inequities in the use...
- The federal Project Grant award, "GLUCOSE PATTERNS AND CLINICAL OUTCOMES IN THE DALLAS HEART STUDY: A PATHWAY TO PRECISION DIABETES - CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEMS", is provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The $819,091 award to The Johns Hopkins University will fund research to use CGM and machine learning methods to identify...
- This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) aims to develop and test a risk mitigation strategy using continuous ketone monitoring (CKM) to enable safer use of SGLT2 inhibitors in patients with Type 1 Diabetes (T1D). The $2,477,577 award to Adventist Health System/Sunbelt Inc. (doing business as AdventHealth Orlando) will fund a...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will evaluate an Adaptive Dietary Intervention (ADI) leveraging Continuous Glucose Monitoring (CGM) for Asian Americans with Type 2 Diabetes (T2D). The $970,016 grant, awarded on September 19, 2025, will be used by New York University (NYU) to examine the feasibility, acceptability, and effects of...
- This federal Project Grant award of $319,990 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports a 12-week randomized controlled trial to compare medical nutrition therapy personalized by continuous glucose monitoring (CGM) feedback to three control interventions in 72 adult participants with type 2 diabetes mellitus. The primary objective is to determine if CGM-informed personalized...
- This $1.2 million project grant from the National Science Foundation's Engineering program (CFDA 47.041) will fund research at Stanford University from September 2022 to August 2026 to develop digital tools and algorithms to improve diabetes care delivery and health equity. Specifically, the university will leverage sensor data and machine learning techniques to better understand patient types and needs, allocate limited provider resources efficiently, and design interpretable treatment...
- This federal Project Grant award of $779,978 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to identify optimal supportive components and adaptive treatment sequences for improving diabetes outcomes and addressing unmet social needs among individuals with high HbA1c levels. The overarching goal is to conduct a 12-month Sequential Multiple Assignment Randomized Trial (SMART) to evaluate...
CONTINUOUS GLUCOSE MONITORING FOR HIGH-RISK TYPE 2 DIABETES IN THE HOSPITAL: CLOUD-BASED REAL-TIME GLUCOSE EVALUATION AND MANAGEMENT SYSTEM (CYBER GEMS) - 7. PROJECT SUMMARY/ABSTRACT THERE IS STRONG EVIDENCE THAT POOR GLYCEMIC CONTROL IN THE HOSPITAL IS COMMON. GIVEN THE KNOWN CONSEQUENCES OF UNCONTROLLED BLOOD SUGARS DURING A HOSPITALIZATION (E.G., INFECTION, SERIOUS NEUROLOGICAL AND CARDIAC COMPLICATIONS, MORTALITY, LONGER LENGTHS OF STAY, READMISSIONS, HIGHER HEALTHCARE COSTS), HEALTH SYSTEMS DEVOTE SIGNIFICANT RESOURCES TO DEVELOPING PROTOCOLS FOR IMPROVING GLUCOMETRICS. SURPRISINGLY, DESPITE THE WIDESPREAD USE AND DEMONSTRATED EFFECTIVENESS OF CONTINUOUS GLUCOSE MONITORING (CGM) FOR AMBULATORY GLUCOSE MANAGEMENT, CGMS ARE NOT CURRENTLY USED IN ANY US HOSPITAL. THEREFORE, THE LONG-TERM GOAL TO DEVELOP CLOUD-BASED REAL-TIME GLUCOSE EVALUATION AND MANAGEMENT SYSTEM (CYBER GEMS) IS TO PROVIDE AN EFFECTIVE, REAL-TIME SOLUTION TO AUGMENT EXISTING PROCESSES, TO PROVIDE A VALUABLE TEST OF REAL-WORLD EFFECTIVENESS, WHILE CAPITALIZING ON STANDARDIZED ALGORITHMS TO FACILITATE SUSTAINABILITY AND SCALABILITY TO OTHER SYSTEMS AND AT-RISK POPULATIONS. THE INNOVATIVE INTERVENTION WILL ENABLE HOSPITAL CARE TEAMS TO TAKE IMMEDIATE STEPS BASED ON THE WIRELESS TRANSMISSION OF GLUCOSE DATA FROM THE DEXCOM G6 DEVICE, SENT TO A DIGITAL DASHBOARD, WHERE INTEGRATION WITH EXISTING REAL-WORLD HOSPITAL PROCESSES CAN PROVIDE IMMEDIATE PRIORITIZATION TO PREVENT OR CORRECT IMPENDING HYPOGLYCEMIA AND SEVERE HYPERGLYCEMIC EVENTS. THE FIRST STEP TOWARD THIS LONG-TERM GOAL IS A RANDOMIZED CONTROLLED TRIAL, DEFINED AS A PHASE III/IV DEFINITIVE CLINICAL TRIAL THAT IN TURN ESTABLISHES EFFICACY AND EFFECTIVENESS OF THIS INTERVENTION. AIM 1 WILL ESTABLISH THE EFFECTIVENESS OF CYBER GEMS VERSUS USUAL CARE (UC) IN INCREASING THE % TIME PATIENTS ARE IN-RANGE AND DECREASING % TIME IN HYPOGLYCEMIA AND SEVERE HYPERGLYCEMIA DURING HOSPITALIZATION. SIMULTANEOUSLY, AIM 2 WILL EVALUATE THE EFFECTIVENESS OF CYBER GEMS VERSUS UC IN DECREASING HOSPITAL-ACQUIRED INFECTION RISK. THE DESCRIBED DIGITAL DASHBOARD IS PROGRESSIVE, AS IT FACILITATES REAL-TIME, WIRELESS TRANSMISSION OF GLUCOSE DATA OF A LARGE VOLUME OF PATIENTS SIMULTANEOUSLY; AUTOMATICALLY IDENTIFIES AND PRIORITIZES PATIENTS FOR INTERVENTION; AND DETECTS POTENTIALLY DANGEROUS HYPOGLYCEMIC EPISODES - ALL AT A REDUCED BURDEN THAN CURRENT METHODS OF STRATIFICATION AND REVIEW. THE UNINTERRUPTED COVERAGE BY TELEMETRY, COUPLED WITH EFFICIENT AND REMOTE DIABETES SPECIALIST OVERSIGHT IN CYBER GEMS IS A SCALABLE, NOVEL, TEAM-BASED APPROACH TO MAXIMIZE THE USE OF CONTINUOUSLY STREAMING CGM DATA FOR OPTIMAL GLUCOSE MANAGEMENT. THE WORK PROPOSED PUSHES THE LIMITS OF THESE CHALLENGES BY PROVIDING EVIDENCE, IDENTIFIED BY A TEAM-BASED APPROACH TO GLUCOSE MANAGEMENT IN AN UNDERSERVED AND UNDERSTUDIED POPULATION, SUPPLEMENTING PRIOR DATA DESIGNED TO IMPROVE OUTCOMES AMONG HIGH-RISK PATIENTS WITH T2D AND RELATED CARDIOMETABOLIC CONDITIONS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $615.1k | 6/3/25 | ||
| Not listed | $0 | 4/29/25 | ||
| Not listed | $0 | 4/29/25 | ||
| Not listed | $80.7k | 8/26/24 | ||
| Not listed | $80.7k | 8/26/24 |